Affordable Access

Publisher Website

Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: Results of the EVAN-65 study

Authors
Journal
Vaccine
0264-410X
Publisher
Elsevier
Publication Date
Volume
26
Issue
16
Identifiers
DOI: 10.1016/j.vaccine.2008.02.021
Keywords
  • Pneumococcal Polysaccharide Vaccine
  • Community-Acquired Pneumonia
  • Pneumococcal Pneumonia
  • Mortality
  • Elderly
Disciplines
  • Medicine

Abstract

Summary A prospective cohort study evaluating the clinical effectiveness of the 23-valent pneumococcal polysaccharide vaccine was conducted among 1298 Spanish older adults with chronic respiratory diseases (bronchitis, emphysema or asthma) who were followed between 2002 and 2005. Main outcomes were all-cause community-acquired pneumonia (CAP) and 30 days mortality from CAP. The association between vaccination and the risk of each outcome was evaluated by multivariable Cox proportional-hazard models adjusted for age and comorbidity pneumococcal vaccination did not alter significantly the risk of overall CAP (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.56–1.07) and 30 days mortality from CAP (HR: 0.87; 95% CI: 0.33–2.28). However, a borderline significant reduction of 30% in the risk of all-cause hospitalisation for CAP was observed among vaccinated subjects (HR: 0.70; 95% CI: 0.48–1.00; p = 0.052). The effectiveness of the vaccine on the combined endpoint of pneumococcal and unknown organism infections reached 34% (HR: 0.66; 95% CI: 0.43–1.01; p = 0.059). Although our findings suggest moderate benefits from the vaccination, the evidence of clinical effectiveness appears limited.

There are no comments yet on this publication. Be the first to share your thoughts.